VivoSeq
Oncology

Chronic Myelogenous Leukemia

113

Pipeline Programs↗

11

Active Trials↗

41

Companies Involved↗

Chronic Myelogenous Leukemia is a highly competitive landscape with 113 programs across 41 companies. The most active players are Bristol-Myers Squibb, Genzyme, a Sanofi Company, Sentynl Therapeutics, Inc.. 12 therapies are approved with 17 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

72/100

Pipeline Velocity

11/100

Mech. Concentration

5/100

Completion Rate

80/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

3 programs

Phase 1G

Genzyme, a Sanofi Company

1 program

Phase 1S

Sentynl Therapeutics, Inc.

1 program

Phase 1C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 1Eisai logo

Eisai

1 program

Phase 1Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Small molecule

88 of 110 classified programs — the dominant modality here.

20%ALL OTHERSProtein / enzyme109%Monoclonal antibody55%Vaccine33%Cell therapy22%RNA therapy1<1%Gene therapy1<1%

Small molecule leads; the ring shows all 110 classified programs, each share of the total. Modality classified for 98% of 121 pipeline programs.

Analysis

Trial Status

153

clinical trials

Completed105 · 69%
Terminated21 · 14%
Unknown status10 · 7%
Active, not recruiting6 · 4%
Withdrawn6 · 4%
Recruiting4 · 3%
Other1 · 1%

Clinical Trials

Trial Activity

153 trials

TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia
Recruiting·SShenzhen TargetRx Co., Ltd.·Phase 1·NCT06088888·90 enrolled
TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
Recruiting·SShenzhen TargetRx Co., Ltd.·Phase 2·NCT06453902·40 enrolled
A Phase II, Multicenter, Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Asciminib in Pediatric Participants Newly Diagnosed or Previously Treated With Philadelphia Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) With or Without Known T315I Mutation
Recruiting·Novartis logoNovartis·Phase 2·NCT07354074·50 enrolled
An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment
Recruiting·Novartis logoNovartis·Approved·NCT04877522·347 enrolled
Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04188405·20 enrolled
TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients
Active, not recruiting·SShenzhen TargetRx Co., Ltd.·Phase 1·NCT05434312·90 enrolled
Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02689440·155 enrolled
Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase
Active, not recruiting·CCentre Leon Berard·Phase 2·NCT04070443·170 enrolled
Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
Active, not recruiting·Novartis logoNovartis·Phase 2·NCT05384587·34 enrolled
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
Active, not recruiting·Novartis logoNovartis·Phase 3·NCT05456191·568 enrolled
TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients
Not yet recruiting·SShenzhen TargetRx Co., Ltd.·Phase 3·NCT07489755·180 enrolled
Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00129740·148 enrolled
Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia
Completed·National Cancer Institute (NCI)·Phase 2·NCT00054431·80 enrolled
A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Completed·Novartis logoNovartis·Phase 3·NCT00471497·846 enrolled
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT00123474·724 enrolled
Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)